Ann: Phase III prophylaxis trial for CS-8958 , page-13

Without major instituational investors' support, it is no surprise that the share price is hammered like this.

IMO,the efficacy rate of almost 50% is actually very good if it is used during pandemic time. The vacines are effective for their specific types of flu and also do not have 100% effective rate. Inavir can cover most of the types and should be much better altough the current trial shows only about 50% efficacy rate. It is at least effective.

The only thing negative is the delay to the market for Lani. We need to know how the US trails program is going on.

Just before "the 59th Annual Meeting of the Japanese Society of Chemotherapy", The share price rose 10% on 22nd June. The meeting started on 23rd June, which was next day. After the meeting started, the share price dropped steadily. now the sharp drop occurs when the news is released by BTA.

What does that imply?




Just my thoughts